Orphazyme A/S

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Strategic Partners A/S is a biopharmaceutical company, which engages in the research and development of treatments for rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Orphazyme A/SCompany announcement                                                                                        No. 09/2021                                                                                                            Company Registration No. 32266355

Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") has released a new investor presentation that outlines its momentum ahead of potential U.S. and European approval of arimoclomol for the treatment of Niemann-Pick disease Type C ("NPC"). The March 2nd presentation can be foun

CytRx Highlights Orphazyme's Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") has announced the appointment of Christophe Bourdon as its new Chief Executive Officer, effective as of April 1, 2021. This appointment comes as Orphazyme awaits potential Food and Drug Administration ("FDA")

CytRx Highlights Orphazyme's Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Company announcement No. 06/2021Company Registration No. 32266355

Orphazyme reports business highlights and financial results in Annual Report 2020

Orphazyme A/SCompany announcement                                                                                        No. 05/2021Inside informationCompany Registration No. 32266355

Orphazyme appoints Christophe Bourdon as Chief Executive Officer

Orphazyme A/SInvestor news                                                                                                        No. 04/2021                                                                                                            Company Registration No. 32266355

Orphazyme announces participation in upcoming virtual investor conferences

Orphazyme A/SInvestor news                                                                                                        No. 03/2021                                                                                                            Company Registration No. 32266355

Orphazyme announces presentation of 2020 Annual Report

LONDON--(BUSINESS WIRE)---- $ORPH #COVID--Open Orphan (AIM:ORPH) announced the world's first COVID-19 characterization study has received ethics approval in the UK.

Ethics Approval Granted for Open Orphan's COVID-19 Human Challenge Study Model

Orphazyme USInvestor news                                                                                                          No. 02/2021

Orphazyme to showcase data on arimoclomol in Niemann-Pick disease Type C during the 2021 Annual WORLDSymposium™

Copenhagen, Denmark, February 1, 2021 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme's shares by persons discharging managerial responsibilities in Orphazyme

Reporting of transactions in Orphazyme's shares made by persons discharging managerial responsibilities

Orphazyme A/SCompany announcement                                                                                        No. 02/2021                                                                                                           Company Registration No. 32266355

Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares

Orphazyme A/SInvestor news                                                                                                        No. 01/2021                                                                                                           Company Registration No. 32266355

Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today provided an update on the U.S. Food and Drug Administration's (“FDA”) review of Orphazyme A/S's (NASDAQ: ORPH) (“Orphazyme”) New Drug Application (“NDA”) for arimoclomol to treat Niemann-Pick Disease Type C (“NPC”). According to Orphazyme, the FDA has extended the rev

CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announced today the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC) by a standard extension period of three months. This extension is necessary for the FDA to complete its review. The updated Prescription Drug User Fee Act (PDUFA) target action date is June 17, 2021.

Orphazyme provides regulatory update on arimoclomol for NPC

Orphazyme A/SCompany announcement                                                                                         No. 72/2020Inside informationCompany Registration No. 32266355

Kim Stratton, CEO, resigns from Orphazyme

Global executive team expanding to support growth plans with three U.S.-based leaders

Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization

CytRx

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA) (NASDAQ:ORPH) (“Orphazyme”) has submitted a Marketing Authorisation Application (“MAA”) to the European Medicines Agency (“EMA”) for arimoclomol in the treatment of Niemann-Pick disease Type C (“NPC”). CytRx has an agreement with

CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C

­­Orphazyme A/SCompany announcement                                                                                        No. 70/2020                                                                                                          Company Registration No. 32266355

Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C

Orphazyme A/SCompany announcement                                                                                        No. 67/2020                                                                                                           Company Registration No. 32266355

Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020

Due to unfortunate timing, Orphazyme listing on NASDAQ did not go smoothly.

Orphazyme: Recent Weakness Presents A Buying Opportunity

Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) in the U.S. and a concurrent private placement of ordinary shares in Europe

Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe

Orphazyme has filed to raise $100 million in a U.S. IPO.

Orphazyme Readies $100 Million U.S. IPO Plan

Orphazyme A/SCompany announcement                                                                                        No. 50/2020                                                                                                           Company Registration No. 32266355

Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C

Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer.

News for Orphazyme A/S Stock (ORPH)